SHISA2

Across TCGA pan-cancer cohorts, SHISA2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SHISA2 data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SHISA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHISA2 expression acts as an unfavorable survival marker.

KIRP, STAD, and SARC are the cancer types where SHISA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.132	0.904	<.001	36	view →
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
SARC	OS	Median	All	0.126	0.860	<.001	12	view →
PCPG	DFS	Median	All	0.080	0.768	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.073	0.733	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SHISA2–KIRP (OS)

Open the KIRP breakdown →